Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, ≥18 years at screening~* Able to provide written informed consent to participate in the trial prior to any trial related procedures are performed~* Diagnosis of acromegaly by historical evidence of (persistent or recurrent) acromegaly~* Treatment with a stable dose of octreotide LAR or lanreotide ATG for at least 3 months as monotherapy prior to screening~* IGF-1 levels ≤1xULN at screening~* Adequate liver, pancreatic, renal and bone marrow functions~* Normal ECG~Exclusion Criteria:~* GH ≥2.5 μg/L at screening (cycle)~* Have received medical treatment for acromegaly with pasireotide (within 6 months prior to screening), pegvisomant (within 3 months prior to screening), dopamine agonists (within 3 months prior to screening) or other investigational agents (within 30 days or 5 half-lives prior to screening \[whichever is longer\]~* Patients who usually take octreotide LAR or lanreotide ATG less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)~* Patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated~* Patients who have undergone major surgery/surgical therapy for any cause within 1 month from screening~* Patients who have undergone pituitary surgery within 6 months prior to screening~* Patients who have received prior pituitary irradiation~* Patients with poorly controlled diabetes mellitus (hemoglobin A1c \>8.0%)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAM2029 (octreotide subcutaneous depot) (Type: EXPERIMENTAL): CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
- Matching placebo (Type: PLACEBO_COMPARATOR): Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.

Based on this trial design, predict the completion outcome and termination type (if applicable).